Publications by authors named "M Falchetti"
Over a lifetime, hematopoietic stem cells (HSCs) adjust their lineage output to support age-aligned physiology. In model organisms, stereotypic waves of hematopoiesis have been observed corresponding to defined age-biased HSC hallmarks. However, how the properties of hematopoietic stem and progenitor cells change over the human lifespan remains unclear.
View Article and Find Full Text PDFElucidating mechanisms of T cell development can guide in vitro T cell differentiation from induced pluripotent stem cells (iPSCs) and facilitate off-the-shelf T cell-based immunotherapies. Using a stroma-free human iPSC-T cell differentiation platform, we screened for epigenetic modulators that influence T cell specification and identified the H3K9-directed histone methyltransferases G9a/GLP as repressors of T cell fate. We show that G9a/GLP inhibition during specific time windows of differentiation of hematopoietic stem and progenitor cells (HSPCs) skews cell fates toward lymphoid lineages.
View Article and Find Full Text PDFArticle Synopsis
- - Axitinib, a drug used for advanced kidney cancer, is being tested for effectiveness against glioblastoma, a severe brain tumor, and shows improved results when combined with other treatments
- - Research indicates that axitinib can lead to cellular senescence (aging) in both tumor and normal cells, but using the antioxidant N-Acetyl-L-Cysteine (NAC) may limit this effect in normal cells while preserving its anti-cancer properties
- - The study reveals that NAC combined with axitinib enhances blood vessel health in brain tumors and protects against liver damage from axitinib, suggesting a potential for better treatment outcomes with reduced side effects
Article Synopsis
- AML shows diverse clinical outcomes, with those originating from hematopoietic stem cells (HSCs) being more resistant to chemotherapy.
- Research reveals that AML from HSCs contains more leukemic stem cells (LSCs) compared to AML from progenitor cells.
- Epigenetic profiling suggests that inherited programs from normal HSCs contribute to the aggressive nature of HSC-AML, with RNA polymerase II-mediated transcription posing a potential therapeutic target.
Tumor-associated myeloid-derived cells (MDCs) significantly impact cancer prognosis and treatment responses due to their remarkable plasticity and tumorigenic behaviors. Here, we integrate single-cell RNA-sequencing data from different cancer types, identifying 29 MDC subpopulations within the tumor microenvironment. Our analysis reveals abnormally expanded MDC subpopulations across various tumors and distinguishes cell states that have often been grouped together, such as TREM2+ and FOLR2+ subpopulations.
View Article and Find Full Text PDF